Mandate

Vinge advised Creades on its investment in Apotea

April 28, 2017

Creades AB (publ) (Nasdaq Stockholm) has purchased 4.9 per cent of the shares in Apolea Holding AB, which is the parent company (96.5%) of the Internet pharmacy Apotea AB.

The investment by Creades amounts to a total of SEK 120.5 million.
 
Vinges team consisted of Erik Sjöman and Jesper Ottergren.
 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025